-
1.发明授权公开(公告)号：US12053512B2
公开(公告)日：2024-08-06
申请号：US16465675
申请日：2017-12-05
IPC分类号： G01N33/50 , A61K39/00 , G01N33/569
CPC分类号： A61K39/0011 , G01N33/505 , G01N33/5052 , G01N33/56977 , A61K2039/5158 , A61K2039/605 , A61K2039/6081
摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.
-
公开(公告)号：US20230377686A1
公开(公告)日：2023-11-23
申请号：US18359437
申请日：2023-07-26
发明人： Kevin B. Givechian , Kamil A. Wnuk , Chad Garner , Stephen Charles .Benz , Hermes J. Garban , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： G16B25/10 , C12Q1/6886
CPC分类号： G16B25/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
-
3.发明申请公开(公告)号：US20200185053A1
公开(公告)日：2020-06-11
申请号：US16733013
申请日：2020-01-02
发明人： Shahrooz Rabizadeh , John Zachary Sanborn , Charles Joseph Vaske , Stephen Charles Benz , Patrick Soon-Shiong
摘要： Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.
-
公开(公告)号：US10525040B2
公开(公告)日：2020-01-07
申请号：US15738353
申请日：2016-06-29
发明人： Shahrooz Rabizadeh , Oleksandr Buzko , Paul Weingarten , Heather McFarlane , Connie Tsai , Stephen Charles Benz , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： A61K31/4196 , A61K45/06 , A61K31/538 , A61P35/00 , A61K31/4155 , A61K31/4178 , A61K31/4439
摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
-
5.发明公开公开(公告)号：US20240350603A1
公开(公告)日：2024-10-24
申请号：US18761799
申请日：2024-07-02
IPC分类号： A61K39/00 , G01N33/50 , G01N33/569
CPC分类号： A61K39/0011 , G01N33/505 , G01N33/5052 , G01N33/56977 , A61K2039/5158 , A61K2039/605 , A61K2039/6081
摘要： The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:
a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.-
公开(公告)号：US20220403007A1
公开(公告)日：2022-12-22
申请号：US17843247
申请日：2022-06-17
IPC分类号： C07K16/00 , G16B5/00 , G16B20/00 , G16B30/00 , G16B35/00 , G16C20/60 , A61K35/17 , C07K16/30 , C07K16/32 , C12Q1/6886 , G16B20/30 , G16B20/20 , G16B35/20 , G16B20/50 , A61P35/00 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/735
摘要： Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
-
公开(公告)号：US20190392288A1
公开(公告)日：2019-12-26
申请号：US16559592
申请日：2019-09-03
发明人： Kamil Wnuk , Jeremi Sudol , Shahrooz Rabizadeh , Patrick Soon-Shiong , Christopher Szeto , Charles Vaske
摘要： Techniques are provided for predicting DNA accessibility. DNase-seq data files and RNA-seq data files for a plurality of cell types are paired by assigning DNase-seq data files to RNA-seq data files that are at least within a same biotype. A neural network is configured to be trained using batches of the paired data files, where configuring the neural network comprises configuring convolutional layers to process a first input comprising DNA sequence data from a paired data file to generate a convolved output, and fully connected layers following the convolutional layers to concatenate the convolved output with a second input comprising gene expression levels derived from RNA-seq data from the paired data file and process the concatenation to generate a DNA accessibility prediction output. The trained neural network is used to predict DNA accessibility in a genomic sample input comprising RNA-seq data and whole genome sequencing for a new cell type.
-
公开(公告)号：US20190018017A1
公开(公告)日：2019-01-17
申请号：US16060638
申请日：2016-12-11
发明人： Stephen Charles Benz , Todd Hembrough , Shahrooz Rabizadeh , John Zachary Sanborn , Charles Joseph Vaske , Fabiola Cecchi , Peter Fasching , Patrick Soon-Shiong
IPC分类号： G01N33/574 , A61K39/395 , C07K16/32 , A61K31/337
摘要： Various protein markers can be used as post-treatment relapse predictors in HER2 positive breast cancer. Notably, these markers appear to be independent of the size of the tumor, metastasis status, grade, and hormone receptor status. In addition, HER2 quantities were in large part not correlated with likelihood of relapse.
-
公开(公告)号：US11756651B2
公开(公告)日：2023-09-12
申请号：US16767366
申请日：2018-12-21
发明人： Kevin B. Givechian , Kamil A. Wnuk , Chad Garner , Stephen Charles Benz , Hermes J. Garban , Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong
IPC分类号： G16B25/10 , C12Q1/6886
CPC分类号： G16B25/10 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
-
公开(公告)号：US10748056B2
公开(公告)日：2020-08-18
申请号：US16559592
申请日：2019-09-03
发明人： Kamil Wnuk , Jeremi Sudol , Shahrooz Rabizadeh , Patrick Soon-Shiong , Christopher Szeto , Charles Vaske
摘要： Techniques are provided for predicting DNA accessibility. DNase-seq data files and RNA-seq data files for a plurality of cell types are paired by assigning DNase-seq data files to RNA-seq data files that are at least within a same biotype. A neural network is configured to be trained using batches of the paired data files, where configuring the neural network comprises configuring convolutional layers to process a first input comprising DNA sequence data from a paired data file to generate a convolved output, and fully connected layers following the convolutional layers to concatenate the convolved output with a second input comprising gene expression levels derived from RNA-seq data from the paired data file and process the concatenation to generate a DNA accessibility prediction output. The trained neural network is used to predict DNA accessibility in a genomic sample input comprising RNA-seq data and whole genome sequencing for a new cell type.
-
-
-
-
-
-
-
-
-
搜索结果
100 条记录 (耗时 0.021 秒)
